Can a gene test tell who responds to immunotherapy for bladder cancer?
NCT ID NCT04953104
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tumors have these mutations will receive nivolumab. The goal is to see if these biological markers can help select patients who will benefit most from this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nivolumab (Opdivo) and relatlimab
- What this could lead to
- If successful, this could help doctors identify which patients with advanced bladder cancer are most likely to benefit from immunotherapy, making treatment more personalized.
- What could go wrong
- This is a very small, early-phase trial with only 6 participants. It is designed to test a biomarker, not to prove a new treatment works. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- A simple blood draw could detect bladder Cancer's return — a trial puts it to the test
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New drug option for Hard-to-Treat cancers with FGFR3 mutations
- New bladder cancer drug aims to fight tumors without harming nerves
- New hope for advanced bladder cancer? bevacizumab combo tested